Depression Drugs Market Forecast, Trend Analysis & Competition Tracking – Global Review 2018 - 2026

Published on : Mar-2019 | List of Tables : 87 | List of Figures : 50 | No. of Pages : 288 | Report Code : FACT3215MR | Format : ppt pdf Excel Word

Depression comprises multiple mental health challenges characterized by the absence of positivity, which leads to feelings such as misery, sadness, and anxiety. Such feelings are normal only if they exist for a short period of time and it becomes a serious condition when the individual feels lost, angry, frustrated, and gloomy very frequently. Although prevalence of depression has gone up in the last decade, demand for depression drugs has witnessed a decline, as other forms of therapies, notably cognitive behavior therapy (CBT) has gained popularity.

Increasing Inclination Towards Non-pharmacological Therapies to Beset Growth of the Global Depression Drugs Market

According to a study by the National Institute of Mental Health, over 10 Mn adults in the U.S. suffered from at least one depressive episode with severe results in 2016. The same study captured that the prevalence of depression is higher among female adults with 8.5% of cases as compared to 4.8% male adults.

Increase in the geriatric population and chronic diseases have been the crucial drivers for the growth of depression drugs market. With the rise in the health consciousness among the consumers, side-effects of the depression drugs are recognized and advanced technologies for the development of drugs with lesser side-effects are being used. However, the inclination of the consumers towards non-pharmacological therapies like CBT and meditation is likely to beset the growth of the global depression drugs market.

US Continues to Push Demand for Depression Drugs

North America constitutes the largest share of the global depression drugs market, given the high concentration of established market players, which are focusing on enhancing the efficiency of these drugs. In addition, a rise in the awareness pertaining to the depression disorders created by mental healthcare organizations is expected to drive the growth of the market in this region. However, with increasing awareness pertaining to the health threats posed by the side-effects of the depression drugs, the consumers are gradually favoring non-clinical treatments over these drugs, which is anticipated to challenge the growth of the global market.

Following the trends of North America, Europe accounts for the second largest share of the depression drugs market, which can be attributed to the proliferated research and development activities to rethink the efficiency of depression drugs in this region.

Side Effects and Vulnerability to Addiction Create Reluctance among Patients

According to the study, depression drugs lose their efficacy after a few months or years since the brain becomes less responsive to such drugs. As a result, the normal brain functions begin to hamper. Symptoms such as blurred vision, vivid dreams, insomnia, fatigue, dizziness, and loss of coordination are observed by the patients who discontinue the intake of the drugs. These after-effects caused by these drugs are anticipated to limit the growth of the global depression drugs market.

Global Depression Drugs Market – Competitive Matrix

According to the report, the significant players operating in the depression drugs market comprise of Johnson and Johnson, Sebela Pharmaceutical Inc., Takeda Pharmaceutical Company Ltd., GlaxoSmithKline, Novartis AG, Allergan USA Inc., AstraZeneca, Pfizer Inc., Eli Lilly and Company, Otsuka Pharmaceutical Co., Ltd., Alkermes Plc, Bristol Myers Squibb Co., H. Lundbeck, and Teva Pharmaceutical Industries Ltd., among others.

These leading players of the depression drugs market are adopting sustainable growth strategies to diversify their product portfolio, sustain their position in the global market, intensify their customer base, and garner share in the global depression drugs market.

Report Description

Fact.MR analysis the global depression drugs market for the forecast period 2018 – 2026. The exhaustive study is aimed at recognizing lucrative opportunities available in the global depression drugs market. The study offers updates and insights into various categories of the depression drugs market. The comprehensive study begins with a detailed overview of the depression drugs market, which assesses the market performance in terms of revenue, key trends, restraints, and drivers prevailing in the global depression drugs market.

Depression Drugs Market - Overview

Fact.MR offers accurate data depending on supply side, demand side, and dynamics of the global depression drugs market. This comprehensive study encompasses market forecast in terms of revenue (US$ Mn). This in-depth study also offers stats on Year-on-Year (Y-o-Y) growth of the depression drugs market.

Key information about the depression drugs market share is drawn through regional pricing trends. Market size and forecast for each section have been incorporated in terms of the global and regional depression drugs markets. The market has been weighed based on the robust demand determinants. The values used for calculating the market size are obtained through primary researches carried out by setting up interviews with a number of manufacturers, distributors, and suppliers of the depression drugs market.

Depression Drugs Market - Segmentation

With a view to understanding and evaluating the growth prospects of the global depression drugs market, this incisive report is segmented into four key sections based on the distribution channel, disease type, region, and drug class. Based on the distribution channel, the depression drugs market is classified into Hospital pharmacies, Retail Pharmacies, and Online Pharmacies.

Depending on the disease type, the depression drugs market is categorized into major depression disorders, Schizophrenia and bipolar I, SSRI induced, and others. Based on the drug class, the depression drugs market is fragmented into Selective serotonin reuptake inhibitors, atypical antipsychotics, Serotonin-norepinephrine reuptake inhibitors, CNS stimulants, and others.

Depending on the regions, the depression drugs market is bifurcated into North America, Europe, Latin America, the Middle East and Africa, and Asia Pacific.

Depression Drugs Market - Research Methodology

In order to assess the overall size of the depression drugs market, primary and secondary research has been carried out. This exclusive study includes prediction of the global market value generated by the sales of depression drugs in the retail pharmacies. Facts and figures of the market have been estimated based on the secondary and primary research of the global depression drugs market.

This exhaustive report has been compiled by keeping the crucial end users and their potential applications in mind, the data for which is obtained from the secondary sources and feedback derived from the primary respondents.

Bottom-up approach has been employed to assess the global depression drugs market depending on the regional segmentation. The market numbers for the segmentations are culled by the bottom-up approach and the same has been included in this research report. The depression drugs market is evaluated in terms of current currency rates. The prediction of the depression drugs market has been done in terms of the absolute dollar opportunity, which is used to measure the level of opportunities present in the global depression drugs market.

Depression Drugs Market – Competitive Matrix

According to the report published by Fact.MR, the global depression drugs market comprise of Johnson and Johnson, Sebela Pharmaceutical Inc., Takeda Pharmaceutical Company Ltd., GlaxoSmithKline, Novartis AG, Allergan USA Inc., AstraZeneca, Pfizer Inc., Eli Lilly and Company, Otsuka Pharmaceutical Co., Ltd., Alkermes Plc, Bristol Myers Squibb Co., H. Lundbeck, and Teva Pharmaceutical Industries Ltd., among others. These significant players have been employing sustainable growth tactics to diversify the product portfolio, maximize their geographical outreach, increase their customer base, and secure higher share in the global depression drugs market. 

1. Preface
     1.1. Market Segmentation
     1.2. Key Research Objectives
     1.3. Research Highlights

2.  Assumptions and Acronyms Used

3. Research Approach & Methodology
     3.1. Research Methodology overview
     3.2. Project Initiation
     3.3. Secondary Research Methodology
     3.4. Primary Research Methodology
     3.5. Analysis Research Methodology
     3.6. Final Report & Conclusions Research Methodology

4. Executive Summary: Global Depression Drugs Market

5.  Market Overview
     5.1. Overview
     5.2. Key Industry Events and Developments
     5.3. Global Depression Drugs Market Forecast and Analysis
     5.4. Global Depression Drugs Market Outlook

6. Market Dynamics
     6.1. Drivers and Restraints Snapshot Analysis
     6.2. Drivers
     6.3. Restraints
     6.4. Opportunities
     6.5. Key Trends
     6.6. Pipeline Analysis
     6.7. Depression Treatment Market Value Chain Analysis

7. Global Depression Drugs Market, by Drug Class
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Depression Drugs Market, by Drug Class
            7.3.1. Atypical antipsychotics
            7.3.2. Serotonin-norepinephrine reuptake inhibitors
            7.3.3. Selective serotonin reuptake inhibitors
            7.3.4. CNS stimulants
            7.3.4. Others (Benzodiazepines and miscellaneous antidepressants)
     7.4. Global Depression Drugs Market Share Analysis, by Drug Class
     7.5. Global Depression Drugs Market Forecast, by Drug Class
     7.6. Global Depression Drugs Market Analysis, by Drug Class

8. Global Depression Drugs Market, by Disease Type
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Depression Drugs Market, by Disease Type
            8.3.1. Major Depressive Disorder
            8.3.2. Schizophrenia and bipolar I disorder (manic depression)
            8.3.3. SSRI induced
            8.3.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     8.4. Global Depression Drugs Market Value Share Analysis, by Disease Type
     8.5. Global Depression Drugs Market Forecast, by Disease Type
     8.6. Global Depression Drugs Market Analysis, by Disease Type

9. Global Depression Drugs Market, by Distribution Channel
     9.1. Introduction & Definition
     9.2. Key Findings / Developments
     9.3. Global Depression Drugs Market, by Distribution Channel
            9.3.1. Hospital pharmacies
            9.3.2. Retail pharmacies
            9.3.3. Online pharmacies
     9.4. Global Depression Drugs Market Share Analysis, by Distribution Channel
     9.5. Global Depression Drugs Market Forecast, by Distribution Channel
     9.6. Global Depression Drugs Market Analysis, by Distribution Channel

10. Global Depression Drugs Market, by Region
     10.1. Global Depression Drugs Market Snapshot, by Country/Sub-region
     10.2. Global Depression Drugs Market Analysis, by Region
            10.2.1. North America
            10.2.2. Europe
            10.2.3. Asia Pacific
            10.2.4. Latin America
            10.2.5. Middle East & Africa
     10.3. Global Depression Drugs Market Forecast, by Region

11. North America Depression Drugs Market Analysis
     11.1. Policies and Regulations: U.S.
     11.2. Key Findings
     11.3. North America Depression Drugs Market Overview
     11.4. North America Depression Drugs Market Value Share Analysis, by Drug Class
     11.5. North America Depression Drugs Market Forecast, by Drug Class
            11.5.1. Atypical antipsychotics
            11.5.2. Serotonin-norepinephrine reuptake inhibitors
            11.5.3. Selective serotonin reuptake inhibitors
            11.5.4. CNS stimulants
            11.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
     11.6. North America Depression Drugs Market Value Share Analysis, by Disease Type
     11.7. North America Depression Drugs Market Forecast, by Disease Type
            11.7.1. Major depressive disorder
            11.7.2. Schizophrenia and bipolar I disorder (manic depression)
            11.7.3. Selective serotonin reuptake inhibitors induced
            11.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     11.8. North America Depression Drugs Market Value Share Analysis, by Distribution Channel
     11.9. North America Depression Drugs Market Forecast, by Distribution Channel
            11.9.1. Hospital pharmacies
            11.9.2. Retail pharmacies
            11.9.3. Online pharmacies
     11.10. North America Depression Drugs Market Value Share Analysis, by Country
     11.11. North America Depression Drugs Market Forecast, by Country
            11.11.1. U.S.
            11.11.2. Canada
     11.12. Market Trends North America

12. Europe Depression Drugs Market Analysis
     12.1. Policies and Regulations: Europe
     12.2. Key Findings
     12.3. Europe Depression Drugs Market Overview
     12.4. Europe Depression Drugs Market Value Share Analysis, by Drug Class
     12.5. Europe Depression Drugs Market Forecast, by Drug Class
            12.5.1. Atypical antipsychotics
            12.5.2. Serotonin-norepinephrine reuptake inhibitors
            12.5.3. Selective serotonin reuptake inhibitors
            12.5.4. CNS stimulants
            12.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
     12.6. Europe Depression Drugs Market Value Share Analysis, by Disease Type
     12.7. Europe Depression Drugs Market Forecast, by Disease Type
            12.7.1. Major depressive disorder
            12.7.2. Schizophrenia and bipolar I disorder (manic depression)
            12.7.3. Selective serotonin reuptake inhibitors induced
            12.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     12.8. Europe Depression Drugs Market Value Share Analysis, by Distribution Channel
     12.9. Europe Depression Drugs Market Forecast, by Distribution Channel
            12.9.1. Hospital pharmacies
            12.9.2. Retail pharmacies
            12.9.3. Online pharmacies
     12.10. Europe Depression Drugs Market Value Share Analysis, by Country
     12.11. Europe Depression Drugs Market Forecast, by Country
            12.11.1. Germany
            12.11.2. France
            12.11.3. Italy
            12.11.4. Spain
            12.11.5. U.K.
            12.11.6. Rest of Europe
     12.12. Market Trends Europe

13. Asia Pacific Depression Drugs Market Analysis
     13.1. Policies and Regulations: Asia Pacific
     13.2. Key Findings
     13.3. Asia Pacific Depression Drugs Market Overview
     13.4. Asia Pacific Depression Drugs Market Value Share Analysis, by Drug Class
     13.5. Asia Pacific Depression Drugs Market Forecast, by Drug Class
            13.5.1. Atypical antipsychotics
            13.5.2. Serotonin-norepinephrine reuptake inhibitors
            13.5.3. Selective serotonin reuptake inhibitors
            13.5.4. CNS stimulants
            13.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
     13.6. Asia Pacific depression drugs Market Value Share Analysis, by Disease Type
     13.7. Asia Pacific Depression Drugs Market Forecast, by Disease Type
            13.7.1. Major depressive disorder
            13.7.2. Schizophrenia and bipolar I disorder (manic depression)
            13.7.3. Selective serotonin reuptake inhibitors induced
            13.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     13.8. Asia Pacific Depression Drugs Market Value Share Analysis, by Distribution Channel
     13.9. Asia Pacific Depression Drugs Market Forecast, by Distribution Channel
            13.9.1. Hospital pharmacies
            13.9.2. Retail pharmacies
            13.9.3. Online pharmacies
     13.10. Asia Pacific Depression Drugs Market Value Share Analysis, by Country
     13.11. Asia Pacific Depression Drugs Market Forecast, by Country
            13.11.1. China
            13.11.2. Japan
            13.11.3. India
            13.11.4. Australia & New Zealand
            13.11.5. Rest of Asia Pacific
     13.12. Market Trends Asia Pacific

14. Latin America Depression Drugs Market Analysis
     14.1. Policies and Regulations: Latin America
     14.2. Key Findings
     14.3. Latin America Depression Drugs Market Overview
     14.4. Latin America Depression Drugs Market Value Share Analysis, by Drug Class
     14.5. Latin America Depression Drugs Market Forecast, by Drug Class
            14.5.1. Atypical antipsychotics
            14.5.2. Serotonin-norepinephrine reuptake inhibitors
            14.5.3. Selective serotonin reuptake inhibitors
            14.5.4. CNS stimulants
            14.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
     14.6. Latin America depression drugs Market Value Share Analysis, by Disease Type
     14.7. Latin America Depression Drugs Market Forecast, by Disease Type
            14.7.1. Major depressive disorder
            14.7.2. Schizophrenia and bipolar I disorder (manic depression)
            14.7.3. Selective serotonin reuptake inhibitors induced
            14.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     14.8. Latin America Depression Drugs Market Value Share Analysis, by Distribution Channel
     14.9. Latin America Depression Drugs Market Forecast, by Distribution Channel
            14.9.1. Hospital pharmacies
            14.9.2. Retail pharmacies
            14.9.3. Online pharmacies
     14.10. Latin America Depression Drugs Market Value Share Analysis, by Country
     14.11. Latin America Depression Drugs Market Forecast, by Country
            14.11.1. Brazil
            14.11.2. Mexico
            14.11.3. Rest of Latin America
     14.12. Market Trends Latin America

15. Middle East & Africa Depression Drugs Market Analysis
     15.1. Policies and Regulations: Middle East & Africa
     15.2. Key Findings
     15.3. Middle East & Africa Depression Drugs Market Overview
     15.4. Middle East & Africa Depression Drugs Market Value Share Analysis, by Drug Class
     15.5. Middle East & Africa Depression Drugs Market Forecast, by Drug class
            15.5.1. Atypical antipsychotics
            15.5.2. Serotonin-norepinephrine reuptake inhibitors
            15.5.3. Selective serotonin reuptake inhibitors
            15.5.4. CNS stimulants
            15.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
     15.6. Middle East & Africa Depression Drugs Market Value Share Analysis, by Disease Type
     15.7. Middle East & Africa Depression Drugs Market Forecast, by Disease Type
            15.7.1. Major depressive disorder
            15.7.2. Schizophrenia and bipolar I disorder (manic depression)
            15.7.3. Selective serotonin reuptake inhibitors induced
            15.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     15.8. Middle East & Africa Depression Drugs Market Value Share Analysis, by Distribution Channel
     15.9. Middle East & Africa Depression Drugs Market Forecast, by Distribution Channel
            15.9.1. Hospital pharmacies
            15.9.2. Retail pharmacies
            15.9.3. Online pharmacies
     15.10. Middle East & Africa Depression Drugs Market Value Share Analysis, by Country
     15.11. Middle East & Africa Depression Drugs Market Forecast, by Country
            15.11.1. GCC
            15.11.2. South Africa
            15.11.3. Israel
            15.11.4. Rest of Middle East & Africa
     15.12. Market Trends Middle East & Africa

16. Competition Landscape
     16.1. Competition Matrix
     16.2. Depression Drugs Market Share Analysis, by Company
     16.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            16.3.1. Otsuka Pharmaceutical Co., Ltd.
                     16.3.1.1. Company Description
                     16.3.1.2. Financial Overview
                     16.3.1.3. Recent Developments
                     16.3.1.4. Strategic Overview
                     16.3.1.4. SWOT Analysis
            16.3.2. Eli Lilly and Company
                     16.3.2.1. Company Description
                     16.3.2.2. Financial Overview
                     16.3.2.3. Strategic Overview
                     16.3.2.4. SWOT Analysis
            16.3.3. Pfizer, Inc.
                     16.3.3.1. Company Description
                     16.3.3.2. Financial Overview
                     16.3.3.3. Strategic Overview
                     16.3.3.4. SWOT Analysis
            16.3.4. AstraZeneca plc.
                     16.3.4.1. Company Description
                     16.3.4.2. Financial Overview
                     16.3.4.3. SWOT Analysis
            16.3.5. Novartis AG
                     16.3.5.1. Company Description
                     16.3.5.2. Financial Overview
                     16.3.5.3. Strategic Overview
                     16.3.5.4. SWOT Analysis
            16.3.6. GlaxoSmithKline plc
                     16.3.6.1. Company Description
                     16.3.6.2. Financial Overview
                     16.3.6.3. Strategic Overview
                     16.3.6.4. Recent Developments
                     16.3.6.5. SWOT Analysis
            16.3.7. Takeda Pharmaceutical Company Ltd
                     16.3.7.1. Company Description
                     16.3.7.2. Financial Overview
                     16.3.7.3. Strategic Overview
                     16.3.7.4. SWOT Analysis
            16.3.8. Sebela Pharmaceutical Inc.
                     16.3.8.1. Company Description
                     16.3.8.2. Financial Overview
                     16.3.8.3. Strategic Overview
                     16.3.8.3. SWOT Analysis
            16.3.9. Allergan USA, Inc.
                     16.3.9.1. Company Description
                     16.3.9.2. Financial Overview
                     16.3.9.3. Strategic Overview
                     16.3.9.3. SWOT Analysis
            16.3.10. Johnson & Johnson
                     16.3.10.1. Company Description
                     16.3.10.2. Financial Overview
                     16.3.10.3. Strategic Overview
                     16.3.10.4. SWOT Analysis

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Depression Drugs Market Forecast, Trend Analysis & Competition Tracking – Global Review 2018 - 2026